On February 13, 2024, GeoVax Labs, Inc., a renowned biotechnology company specializing in the development of immunotherapies and vaccines for cancers and infectious diseases, proudly announced significant advancements in its intellectual property assets. These developments were the result of various actions taken by global patent offices.
One notable achievement came from the Japanese Patent Office, which granted GeoVax’s patent application (No. 2022-153352) for “Compositions and Methods for Generating an Immune Response to a Tumor Associated Antigen.” This specific patent encompasses recombinant Modified Vaccinia Ankara (MVA) viral vectors that contain specific MUC-1 nucleic sequences. These sequences play a crucial role in GeoVax’s MUC-1 tumor-associated antigen immunotherapy program.
Furthermore, the U.S. Patent and Trademark Office also played a significant role in bolstering GeoVax’s intellectual property assets. They issued Patent No. 11,896,657 for a “Replication-Deficient Modified Vaccinia Ankara (MVA) Expressing Marburg Virus Glycoprotein (GP) and Matrix Protein (VP40),” as well as Patent No. 11,897,919 for “Multivalent HIV Vaccine Boost Compositions and Methods of Use.” These patents are of utmost importance to GeoVax’s ongoing endeavors in developing effective vaccines for Marburg virus and HIV.
With these recent achievements, GeoVax’s intellectual property portfolio now encompasses an impressive collection of over 115 granted or pending patent applications across 24 patent families. This extensive portfolio serves as a solid foundation for the company’s continued focus on developing vaccines for COVID-19, cancer immunotherapy, and various other critical areas of research.
GeoVax Labs, Inc.
Updated on: 26/02/2024
Debt to equity ratio: Sell
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
ROE: Strong Sell
We did not find social sentiment data for this stock
There are no analysts data to display
GOVX Stock: Price Decline Indicates Bearish Sentiment Among Investors
On February 13, 2024, GOVX stock experienced a decline in its price performance, trading near the bottom of its 52-week range and below its 200-day simple moving average. The price of GOVX shares decreased by $0.09 since the market last closed, marking a significant drop of 3.41%. This decline suggests a bearish sentiment among investors. GOVX stock opened at $2.71, which was $0.07 higher than its previous close. Trading near the bottom of its 52-week range implies that GOVX stock is currently priced relatively low compared to its performance over the past year. However, trading below the 200-day simple moving average suggests a potential downtrend for GOVX stock. Investors should carefully consider these factors and conduct thorough research before making any investment decisions regarding GOVX stock. It is advisable to consult with a financial advisor or professional before making any investment decisions. The information provided here serves as a starting point for further analysis and should not be considered as financial advice.
GOVX Stock Performance: Mixed Results on February 13, 2024 – A Closer Look at Net Income and EPS Figures
On February 13, 2024, GOVX stock experienced mixed performances based on the available data. Firstly, let’s look at the net income figures. In the past year, GOVX reported a net income of -$14.02 million, indicating a loss. However, compared to the previous year, the net income increased by 24.5%. However, when comparing the net income from the third quarter of the previous year to the current quarter, we observe a decrease of 41.86%. Moving on to the earnings per share (EPS) figures, GOVX reported an EPS of -$12.39 over the past year. However, compared to the previous year, the EPS increased by a significant 72.87%. On the other hand, when comparing the EPS from the third quarter of the previous year to the current quarter, there is a decrease of 41.32%. Overall, GOVX stock performances on February 13, 2024, showed mixed results based on the available data. It is crucial for investors to closely monitor future financial reports to gain a more comprehensive understanding of GOVX’s financial health and make informed investment decisions.